320 related articles for article (PubMed ID: 18290913)
21. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
23. [Costs and effects of alternative screening programs against cervical cancer].
Gyrd-Hansen D; Hølund B; Andersen P
Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
Kobayashi T; Goto R; Ito K; Mitsumori K
Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
[TBL] [Abstract][Full Text] [Related]
25. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis.
Bor AS; Koffijberg H; Wermer MJ; Rinkel GJ
Neurology; 2010 May; 74(21):1671-9. PubMed ID: 20498435
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
27. Estimating personal costs incurred by a woman participating in mammography screening in the National Breast and Cervical Cancer Early Detection Program.
Ekwueme DU; Hall IJ; Richardson LC; Gardner JG; Royalty J; Thompson TD
Cancer; 2008 Aug; 113(3):592-601. PubMed ID: 18536027
[TBL] [Abstract][Full Text] [Related]
28. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
[TBL] [Abstract][Full Text] [Related]
29. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
30. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
31. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach.
Wong SS; Leong AP; Leong TY
Stud Health Technol Inform; 2004; 107(Pt 1):104-10. PubMed ID: 15360784
[TBL] [Abstract][Full Text] [Related]
33. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
35. Endoscopic screening for gastric cancer.
Dan YY; So JB; Yeoh KG
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.
Blake DR; Gaydos CA; Quinn TC
Sex Transm Dis; 2004 Feb; 31(2):85-95. PubMed ID: 14743071
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.
Saab S; Ly D; Nieto J; Kanwal F; Lu D; Raman S; Amado R; Nuesse B; Durazo F; Han S; Farmer DG; Ghobrial RM; Yersiz H; Chen P; Schwegel K; Goldstein LI; Tong M; Busuttil RW
Liver Transpl; 2003 Jul; 9(7):672-81. PubMed ID: 12827551
[TBL] [Abstract][Full Text] [Related]
38. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
39. ["Cost-effectiveness" of cervical screening].
Kostova P
Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
[TBL] [Abstract][Full Text] [Related]
40. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
Neville AM; Quinn MA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]